US FDA requires safety labeling changes for GLP-1 drugs over eye condition risk
XLV•The US FDA is requiring safety labeling changes for GLP-1 drugs over a potential increased risk of a serious eye condition, and is informing patients and healthcare providers.
1. FDA safety warning
The US Food and Drug Administration is informing patients and healthcare providers of a potential increased risk of a serious eye condition associated with GLP-1 receptor agonist medications used for diabetes and weight loss.
